You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 4 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 4 findings. Do not include any additional text.

Abstract:
ABSTRACT.INTRODUCTION: Hyperglycaemia occurs frequently in the critically ill, affects outcome adversely, and is exacerbated by enteral feeding. Furthermore, treatment with insulin in this group is frequently complicated by hypoglycaemia. In healthy patients and those with type 2 diabetes, exogenous glucagon-like peptide-1 (GLP-1) decreases blood glucose by suppressing glucagon, stimulating insulin and slowing gastric emptying. Because the former effects are glucose-dependent, the use of GLP-1 is not associated with hypoglycaemia. The objective of this study was to establish if exogenous GLP-1 attenuates the glycaemic response to enteral nutrition in patients with critical illness induced hyperglycaemia.

ABSTRACT.METHODS: Seven mechanically ventilated critically ill patients, not previously known to have diabetes, received two intravenous infusions of GLP-1 (1.2 pmol/kg/min) and placebo (4% albumin) over 270 minutes. Infusions were administered on consecutive days in a randomised, double-blind fashion. On both days a mixed nutrient liquid was infused, via a post-pyloric feeding catheter, at a rate of 1.5 kcal/min between 30 and 270 minutes. Blood glucose and plasma GLP-1, insulin and glucagon concentrations were measured.

ABSTRACT.RESULTS: In all patients, exogenous GLP-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30–270 min GLP-1 (2077 ± 144 mmol/l min) vs placebo (2568 ± 208 mmol/l min); P = 0.02) and the peak blood glucose (GLP-1 (10.1 ± 0.7 mmol/l) vs placebo (12.7 ± 1.0 mmol/l); P < 0.01). The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations. There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 ± 12 pmol/ml) vs. placebo (104 ± 10 pmol/ml); P < 0.01).

ABSTRACT.CONCLUSIONS: Acute, exogenous GLP-1 infusion markedly attenuates the glycaemic response to enteral nutrition in the critically ill. These observations suggest that GLP-1 and/or its analogues have the potential to manage hyperglycaemia in the critically ill.

ABSTRACT.TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry number: ACTRN12609000093280.

Findings:
[["Exogenous glucagon-like peptide-1 infusion", "Control", "Peak blood glucose", "significantly decreased", "In all patients, exogenous GLP-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30\u2013270 min GLP-1 (2077 \u00b1 144 mmol/l min) vs placebo (2568 \u00b1 208 mmol/l min); P = 0.02) and the peak blood glucose (GLP-1 (10.1 \u00b1 0.7 mmol/l) vs placebo (12.7 \u00b1 1.0 mmol/l); P \u003c 0.01)."], ["Exogenous glucagon-like peptide-1 infusion", "Control", "Absolute insulin concentrations", "no significant difference", "The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 \u00b1 2.7) vs. placebo (5.8 \u00b1 1.8); P = 0.02) but there was no difference in absolute insulin concentrations."], ["Exogenous glucagon-like peptide-1 infusion", "Control", "Glucagon concentrations during infusion", "significantly decreased", "There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 \u00b1 12 pmol/ml) vs. placebo (104 \u00b1 10 pmol/ml); P \u003c 0.01)."], ["Exogenous glucagon-like peptide-1 infusion", "Control", "Glycaemic response", "significantly decreased", "In all patients, exogenous GLP-1 infusion reduced the overall glycaemic response during enteral nutrient stimulation (AUC30\u2013270 min GLP-1 (2077 \u00b1 144 mmol/l min) vs placebo (2568 \u00b1 208 mmol/l min); P = 0.02) and the peak blood glucose (GLP-1 (10.1 \u00b1 0.7 mmol/l) vs placebo (12.7 \u00b1 1.0 mmol/l); P \u003c 0.01)."]]